Madrid Newborn Sickle Cell Disease Cohort: clinical outcomes, stroke prevention and survival

• Published in: Annals of hematology Vol. 103; no. 2; pp. 373 - 383
• Main Authors: García-Morin, Marina, Bardón-Cancho, Eduardo J., Beléndez, Cristina, Dulín, Elena, Blanco-Soto, Paula, Puertas-López, Carolina, Prieto-Medina, Mar, Cervera-Bravo, Áurea, Llorente-Otones, Lucía, Pérez-Alonso, Vanesa, San-Román, Sonsoles, Vecilla-Rivelles, Cruz, López-Rubio, Montserrat, Sebastián, Elena, Bellón, José M., Cela, Elena
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2024; Springer Nature B.V
• Subjects: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell - drug therapy; Anemia, Sickle Cell - therapy; Child; Child, Preschool; Hematology; Hemoglobin, Sickle; Humans; Hydroxyurea - therapeutic use; Infant; Infant, Newborn; Medical screening; Medicine; Medicine & Public Health; Oncology; Original Article; Prospective Studies; Sickle cell disease; Stroke; Stroke - epidemiology; Stroke - etiology; Stroke - prevention & control; Newborn sickle cell disease screening; Cohort; Stroke Prevention; Survival; Madrid
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-023-05539-1

In May 2003, Madrid established the universal newborn screening (NBS) for sickle cell disease (SCD). However, there are no studies resembling the evolution of a SCD neonate cohort followed according to national guidelines in Spain. The aim of this study is to describe the morbimortality and the stroke prevention programme in patients diagnosed by SCD NBS in Madrid. This is a multicentre, observational, prospective cohort study between 2003 and 2018; 187 patients diagnosed with SCD were included (151 HbSS, 6 HbSβ 0 , 27 HbSC, 3 HbSβ +), and median follow-up was 5.2 years (0.03–14.9). There were 5 deaths: 2 related to SCD in patients with severe genotype (HbSS/HbSβ 0 ). Overall survival reached 95% and SCD-related survival 96.8%. The most frequent events were fever without focus, vaso-occlusive crises and acute chest syndromes. Eight strokes occurred in 5 patients which led to a 90.7% stroke-free survival in severe genotype patients (first stroke rate, 0.54 per 100 patient-years). Transcranial Doppler (TCD) was performed in 95% of eligible patients; 75% of children with pathological TCD remained stroke-free. Regarding HbSS/HbSβ 0 patients, 50.1% received hydroxyurea and 9.5% haematopoietic stem cell transplantation. This study reflects the evolution of Madrid SCD cohort and provides morbimortality data similar to other developed countries.